SRSF2 and acute myeloid leukemia: Consistent with our findings in MOLM14, both OCI-AML2 and primary SRSF2 mut AML cells demonstrated significant lower sphericity value after RKI-1447 treatment, compared to SRSF2 WT cells (Figures 4B, S10, and S11), while SRSF2 WT primary AML cells did not similarly respond to RKI-1447 treatment, based on the sphericity analysis.